Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.

By L. Carey, Charles M Perou, Chad Livasy, L. Dressler, D. Cowan, K. Conway, G. Karaca, M. A. Troester, C. Tse, S. Edmiston and 7 more. Journal of the American Medical Association (JAMA), 2006

3,950 citations recorded by the source corpus.

Subfields: Cancer Research, Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/2768e970c288c6c90b169e25a46023da34b982d2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Oncology

In Pathology and Forensic Medicine

Citations in the corpus

Deconstructing the molecular portraits of breast cancer (2010, background): “(Millikan et al., 2008; Carey et al., 2006), survival (Perou et al., 2000; Sorlie et al., 2001; Cheang et al., 2009; Hu et al., 2006), and response to treatment (Prat et al., 2010; Nielsen et al., 2010; Parker et al., 2009b; Hugh et al., 2009; Carey et al., 2007; Rouzier et al., 2005a).”
Triple-negative breast cancer--current status and future directions. (2009, background): “Importantly, the prognostic effect of TNBC is independent of poor grade, nodal status, tumor size and treatment [44, 63].”
Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype (2008, background): “A recent population-based study has shown that this subtype is more prevalent in premenopausal African American women (10), which may contribute to the poor outcomes seen among these patients.”
US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. (2014, result): “The higher proportion of advanced stage and high-grade tumors among HR+/HER2+ and HR−/HER2+ case patients also has been reported previously and is consistent with the known aggressiveness of these tumor subtypes compared with HR+/HER2− disease (4,8,13,14).”
Prognostic markers in triple‐negative breast cancer (2007, background): “Previous studies have examined hormone receptornegative tumors,7,29,30 HER2 positive or negative tumors,31,32 and triple-negative ductal carcinoma insitu.33 In a previous study of 657 cases from the Carolina Breast Cancer Study, Carey et al.34 found that 26% of cases were triple-negative.”
Triple Negative Breast Cancer Cell Lines: One Tool in the Search for Better Treatment of Triple Negative Breast Cancer (2010, background): “incidence of TNBC in African American women is two to three times higher than other ethnic groups, although the reason for this has not been elucidated [6, 7].”
Breast Cancer Statistics (2013, background): “In addition, African American women are more likely to be diagnosed with breast cancers with predictors of poor prognosis, such as triple-negative tumors [21, 22].”
Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies (2010, methodology): “Expression of either CK5/6 or epidermal growth factor receptor (EGFR) has been shown to accurately identify basal-like tumours classified using gene expression [7,8], and several published studies have used these markers to subclassify the TNP tumours into a core basal subgroup (CBP), which is equiv”
NEW STRATEGIES FOR TRIPLE NEGATIVE BREAST CANCER – DECIPHERING THE HETEROGENEITY (2014, background): “TNBCs, which account for 15% of all invasive breast cancers, are generally of a higher grade, occur at a higher rate in young and African-American women, and most harbor a basal-like gene expression signature (1, 2).”